RESEARCH PIPELINE
Biohaven’s extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 activation for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder; myostatin inhibition for neuromuscular and metabolic diseases, including obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates for cancer.
GLUTAMATE
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
MYOSTATIN
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
ION CHANNEL
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
INFLAMMATION & IMMUNOLOGY
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
ONCOLOGY
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO